An interventional study of REGE pro in Psoriasis, sponsored by Egyptian Atomic Energy Authority. Completed at 1 site in Egypt. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-27.
Sponsored by Egyptian Atomic Energy Authority · Not applicable, Interventional, and Treatment
Among 54 studies in Psoriasis with a site in Egypt — 16 open to participants now, 16 under way, 2 of them phase 3. Psoriasis · Egypt.
Among the 54 studies in Psoriasis with a site in Egypt, this one is the 41st largest by enrollment of the 43 interventional ones, is one of 2 that started in 2015, is one of 24 with no phase, and was the 7th registered.
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's enrollment of 22 is below the median of 75 across 1,565 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →16 of the 54 studies in Psoriasis with a site in Egypt are open now, in 1 country. Each count lists the studies.
Of the 174 Psoriasis studies recruiting now, 91 (52%) set no upper age limit and 67 (39%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 20 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →54 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2015.
Median enrollment 40 across the 43 interventional studies, 100 across the 11 observational. Of the 27 that completed or were terminated, 2 (7%) have results posted.
3 of 54 have an industry lead sponsor. The 10 most frequent:
Egyptian Atomic Energy Authority is the lead sponsor of 4 studies on the registry; none are open to participants now.
Egyptian Atomic Energy Authority has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
4 of the studies in Psoriasis with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892339Phase 3Cairo UniversityEfficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. | 2026-12-13 |
| NCT07693595Al-Azhar UniversityNailfold Capillaroscopic Changes in Psoriasis | 2026-11-01 |
| NCT07352306Alaa Ashraf Muhammad HelalTopical Diacerein in Psoriasis Vulgaris | 2027-02-01 |
| NCT07713212Cairo UniversityCombined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis | 2027-02-15 |
Among the 54 studies in Psoriasis with a site in Egypt, from their registry updates:
Using of human amniotic membrane extra-cellular matrix as a topical treatment for improving Psoriasis Area and Severity Index (PASI).
Human amniotic membrane extra-cellular matrix was purchased from National center for radiation research and technology, Egypt, under commercial name REGE pro gel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks
Combination Product: REGE pro
REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
Scaling size decrement
REGE pro gel decreased scaling size in patients with sever scales to moderate scale within two weeks, scaling size decrement from moderate to mild within two weeks, and from mild to complete curing within two weeks
Time frame: 2 weeks
Histopathological improvement
Two biopsies were taken from each patient before and at the end of the treatment. It was noted that all histological signs as munro's microabscess and the elongation of rete ridges were absent.
Time frame: 6 weeks
Erythema disappearing
REGE pro gel gradually decreased erythema in patients within 4-6 weeks, these data were collected from applied patients by questionnaire.
Time frame: 4-6 weeks
Ran from Aug 2015 to primary completion in Feb 2016, 6 months.
Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.
Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Egyptian Atomic Energy Authority